Back | Next |
home / stock / scps / scps message board
Subject | By | Source | When |
---|---|---|---|
Delaware trial now scheduled for 2023! | FACT-MASTER | investorshub | 08/16/2022 12:23:13 AM |
Level II bid side looks interesting at the moment. | FACT-MASTER | investorshub | 08/12/2022 3:51:36 PM |
Loaded | heyitsmeagain | investorshub | 07/27/2022 2:35:23 PM |
speculating - the trial is over, however the | FACT-MASTER | investorshub | 07/20/2022 1:08:06 AM |
AH Close .45 | FACT-MASTER | investorshub | 07/01/2022 12:44:35 AM |
CASE CLOSED - MORRIS LASTER MD, ET | FACT-MASTER | investorshub | 07/01/2022 12:42:27 AM |
SOMETHING IS UP!! | FACT-MASTER | investorshub | 07/01/2022 12:41:39 AM |
Last at .42.5 (+15.87%) Volume = 152,988 | FACT-MASTER | investorshub | 06/17/2022 9:47:59 PM |
$SCPS - continuing on the road to Nasdaq compliance. | FACT-MASTER | investorshub | 05/27/2022 11:08:06 PM |
$SCPS - Review of Issues: | FACT-MASTER | investorshub | 05/22/2022 1:27:38 AM |
Departure/Letter of Paul Hopper | FACT-MASTER | investorshub | 05/21/2022 10:23:53 PM |
$SCPS - Q1/2022 Financials | FACT-MASTER | investorshub | 05/19/2022 9:41:09 PM |
Interesting Institutional Activity: | FACT-MASTER | investorshub | 05/16/2022 2:32:39 AM |
$SCPS - Letter from Ashish Sanghrajka | FACT-MASTER | investorshub | 05/14/2022 6:14:58 PM |
$SCPS - Departure of Ashish Sanghrajka. | FACT-MASTER | investorshub | 05/13/2022 9:36:47 PM |
$SCPS - Nasdaq's Listing Rule 5550(a)(2) -minimum | FACT-MASTER | investorshub | 05/13/2022 2:06:46 AM |
$SCPS - Nasdaqs majority independent director requirement: | FACT-MASTER | investorshub | 05/13/2022 2:02:39 AM |
Mount Scopus | FACT-MASTER | investorshub | 05/06/2022 1:30:19 AM |
A greeting to Dr. Raphael (Rafi) Hofstein. | FACT-MASTER | investorshub | 05/06/2022 1:05:40 AM |
https://ih.advfn.com/stock-market/NASDAQ/scopus-biopharma-$SCPS/stock-news/880213 | FACT-MASTER | investorshub | 05/05/2022 3:10:18 PM |
News, Short Squeeze, Breakout and More Instantly...
Scopus BioPharma Inc. Company Name:
SCPS Stock Symbol:
NASDAQ Market:
DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus B...
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: "SCPS"), a biotechnology company developing transformational therapeut...
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS ”) , a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is...